BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

David Michael Hyman, Jean-Yves Blay, Ian Chau, Noopur S. Raje, Maria Elena Elez Fernandez, Juergen Wolf, Florin Sirzen, Maria Luisa Veronese, Lada Mitchell, Igor Puzanov, Jose Baselga, VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). Journal of Clinical Oncology. ,vol. 32, pp. 2533- 2533 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.2533

Hussam Al-Kateb, TuDung T. Nguyen, Eric J. Duncavage, Catherine E. Cottrell, Shashikant Kulkarni, Rakesh Nagarajan, Karen Seibert, Maria Baggstrom, Saiama N. Waqar, John D. Pfeifer, Daniel Morgensztern, Ramaswamy Govindan, Ian S. Hagemann, Siddhartha Devarakonda, Christina M. Lockwood, David H. Spencer, Kalin Guebert, Andrew J. Bredemeyer, Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer. ,vol. 121, pp. 631- 639 ,(2015) , 10.1002/CNCR.29089

Oliver Gautschi, Julie Milia, Bastien Cabarrou, Marie-Virginia Bluthgen, Benjamin Besse, Egbert F Smit, Juergen Wolf, Solange Peters, Martin Früh, Dieter Koeberle, Youssouf Oulkhouir, Martin Schuler, Alessandra Curioni-Fontecedro, Benjamin Huret, Mallorie Kerjouan, Sebastian Michels, Georg Pall, Sacha Rothschild, Gerald Schmid-Bindert, Matthias Scheffler, Rémi Veillon, Luciano Wannesson, Joachim Diebold, Gérard Zalcman, Thomas Filleron, Julien Mazières, None, Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort Journal of Thoracic Oncology. ,vol. 10, pp. 1451- 1457 ,(2015) , 10.1097/JTO.0000000000000625

Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Parkin, David Forman, Freddie Bray, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. ,vol. 136, ,(2015) , 10.1002/IJC.29210

Liza C. Villaruz, Mark A. Socinski, Shira Abberbock, Lynne D. Berry, Bruce E. Johnson, David J. Kwiatkowski, A. John Iafrate, Marileila Varella-Garcia, Wilbur A. Franklin, D. Ross Camidge, Lecia V. Sequist, Eric B. Haura, Mark Ladanyi, Brenda F. Kurland, Kelly Kugler, John D. Minna, Paul A. Bunn, Mark G. Kris, Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium Cancer. ,vol. 121, pp. 448- 456 ,(2015) , 10.1002/CNCR.29042

D. Planchard, T.M. Kim, J. Mazieres, E. Quoix, G.J. Riely, F. Barlesi, P. Souquet, E.F. Smit, H.J.M. Groen, R.J. Kelly, B. Cho, M.A. Socinski, C. Tucker, B. Ma, B. Mookerjee, C.M. Curtis, B.E. Johnson, LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928) Annals of Oncology. ,vol. 25, ,(2014) , 10.1093/ANNONC/MDU438.46

Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Mackiewicz, Daniil Stroiakovski, Michael Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion-Sileni, Kamil Drucis, Ivana Krajsova, Axel Hauschild, Paul Lorigan, Pascal Wolter, Georgina V Long, Keith Flaherty, Paul Nathan, Antoni Ribas, Anne-Marie Martin, Peng Sun, Wendy Crist, Jeff Legos, Stephen D Rubin, Shonda M Little, Dirk Schadendorf, None, Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib The New England Journal of Medicine. ,vol. 372, pp. 30- 39 ,(2015) , 10.1056/NEJMOA1412690

Edward S Kim, Roy S Herbst, Ignacio I Wistuba, J Jack Lee, George R Blumenschein Jr, Anne Tsao, David J Stewart, Marshall E Hicks, Jeremy Erasmus Jr, Sanjay Gupta, Christine M Alden, Suyu Liu, Ximing Tang, Fadlo R Khuri, Hai T Tran, Bruce E Johnson, John V Heymach, Li Mao, Frank Fossella, Merrill S Kies, Vassiliki Papadimitrakopoulou, Suzanne E Davis, Scott M Lippman, Waun K Hong, None, The BATTLE Trial: Personalizing Therapy for Lung Cancer Cancer Discovery. ,vol. 1, pp. 44- 53 ,(2011) , 10.1158/2159-8274.CD-10-0010

Gideon Bollag, Peter Hirth, James Tsai, Jiazhong Zhang, Prabha N. Ibrahim, Hanna Cho, Wayne Spevak, Chao Zhang, Ying Zhang, Gaston Habets, Elizabeth A. Burton, Bernice Wong, Garson Tsang, Brian L. West, Ben Powell, Rafe Shellooe, Adhirai Marimuthu, Hoa Nguyen, Kam Y. J. Zhang, Dean R. Artis, Joseph Schlessinger, Fei Su, Brian Higgins, Raman Iyer, Kurt D’Andrea, Astrid Koehler, Michael Stumm, Paul S. Lin, Richard J. Lee, Joseph Grippo, Igor Puzanov, Kevin B. Kim, Antoni Ribas, Grant A. McArthur, Jeffrey A. Sosman, Paul B. Chapman, Keith T. Flaherty, Xiaowei Xu, Katherine L. Nathanson, Keith Nolop, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma Nature. ,vol. 467, pp. 596- 599 ,(2010) , 10.1038/NATURE09454

Anya M. Litvak, Paul K. Paik, Kaitlin M. Woo, Camelia S. Sima, Matthew D. Hellmann, Maria E. Arcila, Marc Ladanyi, Charles M. Rudin, Mark G. Kris, Gregory J. Riely, Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. Journal of Thoracic Oncology. ,vol. 9, pp. 1669- 1674 ,(2014) , 10.1097/JTO.0000000000000344